



### 14 December 2015

#### **COMPANY DETAILS**

ABN: 62 147 346 334

### PRINCIPAL AND REGISTERED OFFICE

Potash West NL Suite 3 23 Belgravia Street Belmont WA 6104

#### **POSTAL ADDRESS**

PO Box 588 Belmont WA 6984

#### W www.potashwest.com.au

### E info@potashwest.com.au

P +61 8 9479 5386 F +61 8 9475 0847

### **ASX CODE**

**PWN** 

#### **FRANKFURT CODE**

A1JH27

### **OTC PINK**

**PWNNY** 

### CORPORATE

### INFORMATION

(14 December 2015)

268M Ordinary Fully Paid Shares 36M Ordinary Partly Paid Shares 18M Listed Options 3M Unlisted Options

### **BOARD OF DIRECTORS**

Adrian Griffin

(Non-Executive Chairman)

**Patrick McManus** 

(Managing Director)

**Chew Wai Chuen** 

(Non-Executive Director)

Natalia Streltsova

(Non-Executive Director)

### POTASH WEST NL GRANT OF OPTIONS

The Company has today granted a total of 17,750,000 listed options with an exercise price of \$0.07 expiring 30 November 2018. 16,250,000 of these options were approved by shareholders at the 30 November 2015 AGM.

#### About Potash West

Potash West (ASX:PWN) is an exploration company focused on developing large greensand deposits in West Australia's Perth Basin. The Company aims to define a substantial resource base and investigate how best to recover phosphate, potash and other minerals from the Dandaragan Trough. The project is well situated in relation to infrastructure, with close access to rail, power and gas. A successful commercial outcome will allow the Company to become a major contributor to the potash and phosphate markets at a time of heightened regional demand.

The Company has a major land holding over one of the world's largest known glauconite deposits, with exploration licenses and applications covering an area of over 2,600km². Previous exploration indicates glauconite sediments are widespread for more than 150km along strike and 30km in width. Current JORC compliant Indicated Mineral Resources stand at 250Mt at 2.9% P2O5 of phosphate mineralisation and 175Mt at 4.2% K2O, amenable to processing by the K-Max process. A pre-feasibility is in progress for stage 1, production of phosphate fertilisers.

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

### **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

Potash West NL

ABN

-OL DELSOUAI USE OUIM

62 147 346 334

We (the entity) give ASX the following information.

### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- †Class of \*securities issued or to be issued
- (1) \$0.07 listed options expiring 30 November 2018
- (2) \$0.07 listed options expiring 30 November 2018
- (3) \$0.07 listed options expiring 30 November 2018
- Number of \*securities issued or to be issued (if known) or maximum number which may be issued
- (1) 14,250,000 \$0.07 listed options expiring 30 November 2018
- (2) 2,000,000 \$0.07 listed options expiring 30 November 2018
- (3) 1,500,000 \$0.07 listed options expiring 30 November 2018

<sup>+</sup> See chapter 19 for defined terms.

- 3 Principal terms of the \*securities (e.g. if options, exercise price and if partly paid expiry date; \*securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)
- (1) \$0.07 listed options expiring 30 November
- (2) \$0.07 listed options expiring 30 November 2018
- (3) \$0.07 listed options expiring 30 November 2018
- Do the \*securities rank equally in all respects from the \*issue date with an existing +class of quoted \*securities?

If the additional \*securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the dividend, (in the case of a trust, distribution) interest or payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution interest or payment

(1), (2) & (3) No. New class of security – Listed Options exercisable at \$0.07 expiring 30 November 2018. Each option exercised will convert into one Ordinary Fully Paid Share, which will rank equally with the existing Ordinary Fully Paid Shares on issue. The option does not entitle the holder to participate in the next interest or dividend payment.

5 Issue price or consideration

OL DELSONAI USE ONIN

- (1) \$Nil
- (2) \$Nil
- (3) \$Nil
- 6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)
- (1) Part of the placement as announced 25 June 2015 as approved by shareholders at the 30 November 2015 AGM.
- (2) Consultant options as approved by shareholders at the 30 November 2015 AGM.
- (3) Consultant options.
- 6a Is the entity an \*eligible entity that has obtained security holder approval under rule 7.1A?

If Yes, complete sections 6b – 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i

<sup>+</sup> See chapter 19 for defined terms.

6	resolution under rule 7.1A was passed	30 November 2015
6	Number of *securities issued without security holder approval under rule 7.1	(3) 1,500,000 \$0.07 listed options expiring 30 November 2018
6	Number of *securities issued with security holder approval under rule 7.1A	Nil
6	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	<ul> <li>(1) Part of the placement as announced 25 June 2015 as approved by shareholders at the 30 November 2015 AGM.</li> <li>(2) Consultant options as approved by shareholders at the 30 November 2015 AGM.</li> </ul>
6	Number of *securities issued under an exception in rule 7.2	Nil
6	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A
6	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A
6	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Refer to Annexure 1
7	*Issue dates  Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.  Cross reference: item 33 of Appendix 3B.	14 December 2015

<sup>+</sup> See chapter 19 for defined terms.

			Number	+Class
	8	Number and +class of all +securities	232,326,236	Ordinary Fully paid shares
		quoted on ASX (including the *securities in section 2 if applicable)	35,960,024	Ordinary Partly paid shares (paid to \$0.001, unpaid \$0.049)
			17,750,000	\$0.07 listed options expiring 30 November 2018
			Number	†Class
$\bigcirc$	9	Number and *class of all *securities not quoted on ASX ( <i>including</i> the *securities in section 2 if	100,000	\$0.400 unlisted options expiring 8 September 2016
		applicable)	100,000	\$0.600 unlisted options expiring 8 September 2016
			500,000	\$0.15 unlisted options expiring 7 February 2017
			1,992,188	\$0.087 unlisted options expiring 7 November 2017
	10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	N/A	
	Part :	2 - Pro rata issue		
	11	Is security holder approval required?		
	12	Is the issue renounceable or non-renounceable?		
	13	Ratio in which the *securities will be offered		
	14	*Class of *securities to which the offer relates		
	15	<sup>+</sup> Record date to determine entitlements		

<sup>+</sup> See chapter 19 for defined terms.

16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	
17	Policy for deciding entitlements in relation to fractions	
18	Names of countries in which the entity has security holders who will not be sent new offer documents	
	Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	
20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the issue	
23	Fee or commission payable to the	
	broker to the issue	
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	
25	If the issue is contingent on security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	

-Of personal use only

<sup>+</sup> See chapter 19 for defined terms.

28	Date rights trading will begin (if applicable)	
29	Date rights trading will end (if applicable)	
30	How do security holders sell their entitlements in full through a broker?	
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	
32	How do security holders dispose of their entitlements (except by sale through a broker)?	
33	†Issue date	
	3 - Quotation of securities only complete this section if you are applying for quotation of securities	
34	Type of *securities (tick one)	
(a)	*Securities described in Part 1	
(b)	All other *securities  Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities	
Entities that have ticked box 34(a)		
Additional securities forming a new class of securities		
Tick to docume	indicate you are providing the information or nts	
35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders	

AIUO BSM | MUSA OUI

<sup>+</sup> See chapter 19 for defined terms.

36	If the *securities are *equity se *securities setting out the numbe 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over	ecurities, a distribution schedule of the additional r of holders in the categories
37	A copy of any trust deed for the a	dditional ⁺securities
Entitie	es that have ticked box 34(b)	
38	Number of *securities for which *quotation is sought	
39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought	
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?  If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	
41	Reason for request for quotation now  Example: In the case of restricted securities, end of restriction period  (if issued upon conversion of another *security, clearly identify that other *security)	

<sup>+</sup> See chapter 19 for defined terms.

A2 Number and \*class of all \*securities quoted on ASX (including the \*securities in clause 38)

Number	†Class

### **Quotation agreement**

MUO BSM IBUOSIBQ I

- <sup>†</sup>Quotation of our additional <sup>†</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>†</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Patrick McManus Date: 14 December 2015

(Director)

Print name: Patrick McManus

== == == ==

<sup>+</sup> See chapter 19 for defined terms.

### Appendix 3B – Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

### Part 1

Rule 7.1 – Issues exceeding 15% of capital			
Step 1: Calculate "A", the base figure from which the placement capacity is calculated			
Insert number of fully paid <sup>†</sup> ordinary securities on issue 12 months before the <sup>†</sup> issue date or date of agreement to issue	197,914,005		
Add the following:			
Number of fully paid *ordinary securities issued in that 12 month period under an exception in rule 7.2	4,562,231		
Number of fully paid *ordinary securities issued in that 12 month period with shareholder approval	29,850,000		
Number of partly paid *ordinary securities that became fully paid in that 12 month period	Nil		
Note:  Include only ordinary securities here — other classes of equity securities cannot be added  Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed  It may be useful to set out issues of securities on different dates as separate line items			
<b>Subtract</b> the number of fully paid *ordinary securities cancelled during that 12 month period	Nil		
"A"	232,326,236		

<sup>+</sup> See chapter 19 for defined terms.

"B"	0.15
	[Note: this value cannot be changed]
Multiply "A" by 0.15	34,848,935
Step 3: Calculate "C", the amount of pl has already been used	acement capacity under rule 7.1 that
<b>Insert</b> number of *equity securities issued or agreed to be issued in that 12 month period not counting those issued:	
Under an exception in rule 7.2	1,500,000
• Under rule 7.1A	
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>	
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	
"C"	1,500,000
Step 4: Subtract "C" from ["A" x "B"] to capacity under rule 7.1	calculate remaining placement
"A" x 0.15	34,848,935
Note: number must be same as shown in Step 2	
Subtract "C"	1,500,000
Note: number must be same as shown in Step 3	
	İ
<i>Total</i> ["A" x 0.15] – "C"	33,348,935

AUO BSN IBUOSIBÓ JOE

<sup>+</sup> See chapter 19 for defined terms.

### Part 2

Rule 7.1A – Additional placement capacity for eligible entities			
Step 1: Calculate "A", the base figure from which the placement capacity is calculated			
"A"	232,326,236		
Note: number must be same as shown in Step 1 of Part 1			
Step 2: Calculate 10% of "A"			
"D"	0.10		
	Note: this value cannot be changed		
<b>Multiply</b> "A" by 0.10	23,232,624		
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used			
Insert number of *equity securities issued or agreed to be issued in that 12 month period under rule 7.1A			
Notes:			
<ul> <li>This applies to equity securities – not just ordinary securities</li> </ul>			
Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed			
Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security			
holder approval has been obtained			
It may be useful to set out issues of securities on different dates as separate line items			
"E"	0		

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10  Note: number must be same as shown in Step 2	23,232,624	
Subtract "E"  Note: number must be same as shown in Step 3	0	
<i>Total</i> ["A" x 0.10] – "E"	23,232,624  Note: this is the remaining placement capacity under rule 7.1A	

<sup>+</sup> See chapter 19 for defined terms.